The Company expects that cash, cash equivalents, and short-term investments as of March 31, 2025, will enable the Company to fund its operating expenses and capital expenditure requirements through the end of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP:
- Buy Rating for Rapport Therapeutics: Promising Precision Therapeutics for CNS Disorders
- Rapport Therapeutics initiated with an Outperform at Citizens JMP
- Rapport Therapeutics to present data at 2025 AAN meeting
- Buy Rating Affirmed for Rapport Therapeutics Amid Promising RAP-219 Trials and Strong Financial Position
- Rapport Therapeutics Reports 2024 Financial Results and Progress